<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9186">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05703425</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2021001951</org_study_id>
    <nct_id>NCT05703425</nct_id>
  </id_info>
  <brief_title>The Effect of Sulfasalazine on CRH Levels in Pregnant Women</brief_title>
  <official_title>The Effect of Sulfasalazine on CRH Levels in Pregnant Women With a History of Pre-Term Birth: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this randomized clinical trial is to assess sulfasalazine as a potential&#xD;
      treatment to prevent recurrent preterm birth. The main questions it aims to answer are:&#xD;
&#xD;
        -  Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in&#xD;
           pregnant persons with a prior history of preterm birth?&#xD;
&#xD;
        -  Does sulfasalazine reduce the incidence of recurrent preterm birth in pregnant persons&#xD;
           given drug vs. controls?&#xD;
&#xD;
      Consenting participants will be randomized to receive sulfasalazine or to a control group and&#xD;
      will undergo serial blood draws to assess plasma CRH levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to assess the potential for sulfasalazine to prevent recurrent preterm birth.&#xD;
      The investigators' main objective is to assess the effects of sulfasalazine on the maternal&#xD;
      serum biomarker CRH, which is associated with preterm birth.&#xD;
&#xD;
      The will be a pilot randomized controlled trial of pregnant multiparous patients who have had&#xD;
      a prior preterm delivery. Pregnant women with a prior preterm birth are at high risk (about&#xD;
      20-30%) of having a recurrent preterm birth. The goal of the study will be to evaluate the&#xD;
      effect of sulfasalazine on the maternal serum biomarker CRH at 28, 32, and 36 weeks gestation&#xD;
      after randomization of patients to the study drug.&#xD;
&#xD;
      Secondary objectives include evaluating the effect of sulfasalazine on the outcome of&#xD;
      delivery less than 37 weeks gestation in this group of high risk pregnant women. Additional&#xD;
      composite neonatal outcomes will be assessed.&#xD;
&#xD;
      The proposed study has the potential to identify a novel, low-cost, orally available&#xD;
      treatment for preterm delivery based on in vitro evidence and epidemiologic studies&#xD;
      suggesting that sulfasalazine may be an effective intervention to prevent preterm birth. If&#xD;
      the hypothesis put forth by the investigators is confirmed, sulfasalazine would be an&#xD;
      attractive therapeutic intervention that could be implemented for the prevention of preterm&#xD;
      birth in both developed and developing nations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2023</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum CRH levels</measure>
    <time_frame>between 28 and 36 weeks of pregnancy</time_frame>
    <description>CRH will be assessed at 28, 32, and 36 weeks gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous preterm birth &lt; 37 weeks gestation</measure>
    <time_frame>up to 37 weeks of pregnancy</time_frame>
    <description>Preterm births prior to 37 weeks secondary to preterm labor (PTL) or premature Preterm births secondary to preterm labor or preterm rupture of the membranes (PPROM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous preterm birth &lt; 34 weeks gestation</measure>
    <time_frame>up to 34 weeks of pregnancy</time_frame>
    <description>Preterm births prior to 34 weeks secondary to PTL or PPROM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically indicated preterm birth &lt; 37 weeks gestation</measure>
    <time_frame>up to 37 weeks of pregnancy</time_frame>
    <description>Preterm births due to maternal or fetal disease not related to PTL or PPROM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital cervical exam at 36 weeks gestational age</measure>
    <time_frame>between 35 weeks and 36 weeks 6 days of pregnancy</time_frame>
    <description>Digital cervical exam at 36 weeks gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal morbidity</measure>
    <time_frame>From birth of the neonate until 28 days of life</time_frame>
    <description>Composite outcome including but not limited to Apgar neonatal death, respiratory distress, necrotizing enterocolitis, and bronchopulmonary dysplasia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Sulfasalazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant persons will receive sulfasalazine daily with 500 mg/daily and increasing by 500 mg/day every week until they reach a therapeutic dose of 1,000 mg twice daily. Drug will be started at 24 weeks estimated gestational age and ended at 36 weeks or earlier if preterm birth occurs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pregnant persons will receive standard care in pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>Sulfasalazine will be administered between 24 and 36 weeks of pregnancy</description>
    <arm_group_label>Sulfasalazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Participants with a history of prior preterm birth in a previous pregnancy&#xD;
&#xD;
          -  Participants must be between 12 and 22 weeks gestation.&#xD;
&#xD;
          -  Participants must have their pregnancy dates confirmed by ultrasound.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants &lt; 18 years old&#xD;
&#xD;
          -  Participants with a cervical length &lt; 25 mm&#xD;
&#xD;
          -  Participants with a multiple gestation&#xD;
&#xD;
          -  Cerclage&#xD;
&#xD;
          -  Progesterone administration&#xD;
&#xD;
          -  Unwilling or unable to swallow the study agent capsule or consume an inert ingredient&#xD;
             in the study agent capsule&#xD;
&#xD;
          -  Acute liver disease or known liver abnormalities&#xD;
&#xD;
          -  Other significant chronic medical or psychiatric illness that, in the investigator's&#xD;
             opinion, would prevent participation in the study&#xD;
&#xD;
          -  Known hypersensitivity to sulfasalazine&#xD;
&#xD;
          -  Known glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  History of severe asthma&#xD;
&#xD;
          -  Digoxin use&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Intestinal obstruction&#xD;
&#xD;
          -  Urinary tract obstruction&#xD;
&#xD;
          -  Hepatic dysfunction&#xD;
&#xD;
          -  Renal dysfunction&#xD;
&#xD;
          -  Blood dyscrasia such as agranulocytosis, aplastic anemia.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Rosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Robert Wood Johnson Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Fields, MD</last_name>
    <phone>516-816-4343</phone>
    <email>jf993@rwjms.rutgers.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shama Khan, MS</last_name>
    <phone>732-407-6421</phone>
    <email>khansp@rwjms.rutgers.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rutgers Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Fields, MD</last_name>
      <phone>732-235-6632</phone>
      <email>jf993@rwjms.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shama Khan, MS</last_name>
      <phone>732-235-6632</phone>
      <email>khansp@rwjms.rutgers.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McLean M, Bisits A, Davies J, Woods R, Lowry P, Smith R. A placental clock controlling the length of human pregnancy. Nat Med. 1995 May;1(5):460-3. doi: 10.1038/nm0595-460.</citation>
    <PMID>7585095</PMID>
  </reference>
  <reference>
    <citation>Wang B, Parobchak N, Rosen T. RelB/NF-kappaB2 regulates corticotropin-releasing hormone in the human placenta. Mol Endocrinol. 2012 Aug;26(8):1356-69. doi: 10.1210/me.2012-1035. Epub 2012 Jun 25.</citation>
    <PMID>22734038</PMID>
  </reference>
  <reference>
    <citation>Wang B, Parobchak N, Martin A, Rosen M, Yu LJ, Nguyen M, Gololobova K, Rosen T. Screening a small molecule library to identify inhibitors of NF-kappaB inducing kinase and pro-labor genes in human placenta. Sci Rep. 2018 Jan 26;8(1):1657. doi: 10.1038/s41598-018-20147-0.</citation>
    <PMID>29374256</PMID>
  </reference>
  <reference>
    <citation>Norgard B, Fonager K, Pedersen L, Jacobsen BA, Sorensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003 Feb;52(2):243-7. doi: 10.1136/gut.52.2.243.</citation>
    <PMID>12524407</PMID>
  </reference>
  <reference>
    <citation>Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981 Jan;80(1):72-6.</citation>
    <PMID>6108894</PMID>
  </reference>
  <reference>
    <citation>Hensleigh PA, Kauffman RE. Maternal absorption and placental transfer of sulfasalazine. Am J Obstet Gynecol. 1977 Feb 15;127(4):443-4. doi: 10.1016/0002-9378(77)90510-5. No abstract available.</citation>
    <PMID>13655</PMID>
  </reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>January 26, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Todd Rosen, MD</investigator_full_name>
    <investigator_title>Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences</investigator_title>
  </responsible_party>
  <keyword>preterm birth</keyword>
  <keyword>sulfasalazine</keyword>
  <keyword>corticotropin releasing hormone</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be provided to those inquire to the corresponding author of the manuscript if published. If no manuscript is published, inquiries can be directed to the principal investigator of the study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available on publication and remain available for two years.</ipd_time_frame>
    <ipd_access_criteria>The principal investigator will individually assess all requests for data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

